R&D News | pharmaphorum

News

J&J doublet beats Tagrisso in first-line lung cancer

AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in

News

US channels $104m into antimicrobial resistance project

The US government has set aside a $104 million pot of funding for research into bacterial behaviour and antibiotic resistance, in the hope of speeding up diagnosis and ena

News

BridgeBio’s $250m raise heads latest biotech financings

BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloido

News

Ex-Novartis CMO John Tsai pops up at Forcefield

Novartis’ former chief medical officer John Tsai has returned to a senior position in biopharma, taking the role of chief executive of UK start-up Forcefield Therapeutics.

News

Ionis preps filings for olezarsen in rare disease FCS

Ionis Pharma is preparing to file for regulatory approval of its experimental therapy olezarsen for familial chylomicronaemia syndrome (FCS) in the US and Europe after the

News

Takeda joins PIKfyve ALS push with AcuraStem deal

Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug tar

J&J doublet beats Tagrisso in first-line lung cancer

US channels $104m into antimicrobial resistance project

BridgeBio’s $250m raise heads latest biotech financings

Ex-Novartis CMO John Tsai pops up at Forcefield

Ionis preps filings for olezarsen in rare disease FCS

Takeda joins PIKfyve ALS push with AcuraStem deal

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks